Get the Stockscreener App
23.73
0.79%
-0.41
Tvardi Therapeutics Inc stock is traded at $23.73, with a volume of 1,487.
It is down -0.79% in the last 24 hours and up +11.29% over the past month.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
See More
Previous Close:
$24.14
Open:
$24.34
24h Volume:
1,487
Relative Volume:
0.03
Market Cap:
$222.13M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.74%
1M Performance:
+11.29%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.66
$24.34
1-Week Range:
$23.66
$27.76
52-Week Range:
$15.80
$34.31
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
23.73 | 243.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.97 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.42 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.95 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.12 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
Is Tvardi Therapeutics Inc. trending in predictive chart modelsAI Screener for Daily Stock Forecast - Newser
What high frequency data says about Tvardi Therapeutics Inc.Risk Shielded Trade Watch with Analysis - Newser
Volatility clustering patterns for Tvardi Therapeutics Inc.Portfolio Safety Metrics and Return Analysis - Newser
Top chart patterns to watch in Tvardi Therapeutics Inc.Free Beginner Friendly Stock Selection Guide - Newser
Analyzing Tvardi Therapeutics Inc. with risk reward ratio chartsDividend Strategy Summary With 10-Year Outlook - Newser
Published on: 2025-08-04 07:15:03 - metal.it
Does Tvardi Therapeutics Inc. stock perform well during market downturnsUnprecedented profits - Jammu Links News
Should I hold or sell Tvardi Therapeutics Inc. stock in 2025Build a winning investment portfolio - Jammu Links News
Tvardi Therapeutics Inc. Stock Analysis and ForecastGet alerts on high-potential market moves - Jammu Links News
How volatile is Tvardi Therapeutics Inc. stock compared to the marketGet high-impact stock recommendations now - Jammu Links News
Is Tvardi Therapeutics Inc. a good long term investmentInvest confidently with real-time updates - Jammu Links News
What is the risk reward ratio of investing in Tvardi Therapeutics Inc. stockRealize exceptional returns through smart trading - Jammu Links News
How institutional ownership impacts Tvardi Therapeutics Inc. stockDownside Control Plan With Support Analysis - Newser
How does Tvardi Therapeutics Inc. generate profit in a changing economyRapid wealth multiplication - Jammu Links News
What are analysts’ price targets for Tvardi Therapeutics Inc. in the next 12 monthsCapitalize on market momentum for maximum gains - Jammu Links News
What institutional investors are buying Tvardi Therapeutics Inc. stockBuild wealth steadily with smart stock selection - Jammu Links News
What catalysts could drive Tvardi Therapeutics Inc. stock higher in 2025Build wealth steadily with smart stock selection - Jammu Links News
What recovery options are there for Tvardi Therapeutics Inc.Watchlist Summary for Active Day Traders - Newser
Is Tvardi Therapeutics Inc. stock poised for growthDaily Market Momentum and Pressure Analysis - Newser
How to build a custom watchlist for Tvardi Therapeutics Inc.Free Risk Controlled Picks With Real Returns - Newser
Can technical indicators confirm Tvardi Therapeutics Inc.’s reversalHigh Yield Stock Screening Results Explained - metal.it
Published on: 2025-07-31 10:29:26 - metal.it
What makes Tvardi Therapeutics Inc. stock price move sharplyFree Expert Verified Stock Trade Ideas - Newser
Published on: 2025-07-29 11:42:01 - metal.it
Is Tvardi Therapeutics Inc. stock overvalued or undervaluedUnlock daily market insights for better trades - Jammu Links News
What is the dividend policy of Tvardi Therapeutics Inc. stockExplosive capital appreciation - jammulinksnews.com
What are Tvardi Therapeutics Inc. company’s key revenue driversHigh-octane financial growth - Jammu Links News
What is Tvardi Therapeutics Inc. company’s growth strategyBuild a winning investment portfolio - Jammu Links News
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
There is no financial data for Tvardi Therapeutics Inc (TVRD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):